Product Program year 2025 Source: CMS Open Payments

Myfembree

Drug Womens Health

NDC 72974-415-01

Open in the dashboard

General payments

$369,449

17,273 payments

Research payments

$9,327,646

2,996 payments

Through program year 2025, $369,449 in general payments and $9,327,646 in research payments were reported against Myfembree (Womens Health).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2025 General $369,449 17,273
2025 Research $9,327,646 2,996

Breakdown

Who paid General payments · program year 2025
  1. Sumitomo Pharma America, Inc. $369,449 17,273 payments
Top recipients General payments · program year 2025
  1. Amelia Bostwick Obstetrics & Gynecology · Jesup, GA $539 <1% · 20 payments
  2. Karin Young Nurse Practitioner, Women's Health · Pittsburgh, PA $539 <1% · 20 payments
  3. Kevin Khai Tieu Obstetrics & Gynecology · Fountain Valley, CA $503 <1% · 17 payments
  4. Isaac Victor Gynecology · Cranford, NJ $448 <1% · 38 payments
  5. Sean George Urogynecology and Reconstructive Pelvic Surgery · Chicago, IL $444 <1% · 11 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Obstetrics & Gynecology $209,775 59% · 4,403 practitioners
  2. Nurse Practitioner, Family Nurse Practitioner $30,451 9% · 742 practitioners
  3. Nurse Practitioner, Women's Health Nurse Practitioner $24,379 7% · 557 practitioners
  4. Physician Assistant $15,226 4% · 339 practitioners
  5. Gynecology Obstetrics & Gynecology $13,324 4% · 244 practitioners

The top 5 of 76 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $36,366 10% · 678 recipients
  2. Texas $36,143 10% · 741 recipients
  3. New York $31,889 9% · 646 recipients
  4. Florida $25,572 7% · 606 recipients
  5. Georgia $20,149 5% · 464 recipients

The top 5 of 53 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

362

Prescriptions dispensed, refills included

Drug cost

$432,280

Paid at the pharmacy, in all

Prescribers

29

With 11 or more claims of it

Medicare Part D drugs matched to MYFEMBREE, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Myfembree Relugolix/Estradiol/Norethindr Same name 29 362 $432,280

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 29 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Mikio Nihira Obstetrics & Gynecology CA 21 $23,645 None on record
Alexcis Ford Obstetrics & Gynecology GA 15 $17,682 None on record
Jonathan Thomas Obstetrics & Gynecology MO 15 $17,240 None on record
Glenn Bankert Obstetrics & Gynecology FL 14 $16,921 None on record
Anna Marcantel Nurse Practitioner LA 14 $16,091 $17

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 29 with Patron
17,273 general · 2,996 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record